|
Today's Headlines
FDA has approved sumatriptan iontophoretic transdermal system (Zecuity, NuPathe) for the acute treatment of migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin.
» Full article
|
|
The Academy of Managed Care Pharmacy recommends that the Centers for Medicare & Medicaid Services evaluate existing national quality health measures before implementing quality metrics in state health insurance exchanges starting in 2016. » Full article
|
|
FDA approved the first trivalent influenza vaccine (Flublok, Protein Sciences) made using an insect virus (baculovirus) expression system and recombinant DNA technology for the prevention of seasonal influenza disease in people aged 18 to 49 years. » Full article
|
|
Changes in tablet color significantly increase the odds that patients will stop taking their medications, according to a study published online first Dec. 31, 2012, in JAMA Internal Medicine (formerly known as the Archives of Internal Medicine). » Full article
|
|
CONTINUING EDUCATION
Welcome to the fifth activity in our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The January activity covers macrovascular and microvascular complications of diabetes mellitus.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
Multiple sclerosis (MS) is a neurologic disorder of chronic inflammation and demyelination of the central nervous system. The disease affects an estimated 400,000 people in the United States, with an onset in young adulthood. The exact cause of MS is unknown; however, both genetic and environmental factors are believed to be involved. Although there is no cure for MS, drug treatments are available with the goal of decreasing relapses and further disability. Nine agents are currently approved for MS, with interferon and glatiramer established as first-line therapies, although their routes of administration may hamper compliance. Several additional agents, including oral products, are now under investigation for the future treatment of MS. » Full article
|
|
|
Like
Tweet
